Table II.
Individual SNPs associated with recurrence risk in NSCLC patients treated with curative therapy
| SNP | Gene | Chr | MAF | SNP location | Allelic change | Overall | |||
|---|---|---|---|---|---|---|---|---|---|
| Best model | HR (95% CI)a | P value | q value | ||||||
| rs2536182 | WNT16 | 7 | 0.48 | 3′ flanking | G>C | Dominant | 0.49 (0.33–0.73) | 3.87×10−4 | 0.067 |
| rs7296283 | LRP6 | 12 | 0.18 | 5′ flanking | G>A | Dominant | 1.84 (1.24–2.72) | 2.30×10−3 | 0.188 |
| rs10898563 | FZD4 | 11 | 0.37 | 3′ UTR | A>G | Recessive | 2.00 (1.26–3.17) | 3.30×10−3 | 0.188 |
| SNP | Surgery-only | Surgery and chemotherapy | |||||||
| Best model | HR (95% CI)b | P value | q value | Best model | HR (95% CI)b | P value | q value | ||
| rs2536182 | Dominant | 0.47 (0.28–0.80) | 5.24×10−3 | 0.154 | Dominant | 0.64 (0.27–1.53) | 0.3554 | 0.259 | |
| rs10898563c | Recessive | 2.98 (1.60–5.35) | 4.31×10−4 | 0.105 | Dominant | 0.60 (0.29–1.22) | 0.1554 | 0.259 | |
| rs11725638d | Dominant | 1.29 (0.75–2.22) | 0.3486 | 0.368 | Dominant | 0.31 (0.14–0.67) | 3.05×10−3 | 0.242 | |
Underlined bold numbers denote significant association at q < 0.1. MAF, minor allele frequency; UTR, untranslated region.
aAdjusted for sex, age, race, clinical stage, pack year tobacco history and treatment regimen.
bAdjusted for sex, age, race, clinical stage and pack year tobacco history.
cTop SNP in surgery-only group.
dTop SNP in surgery and chemotherapy group.